Key Takeaways
- Canadian hospitals have committed over $340 million to AI diagnostic tool procurement in 2025-2026, a 3.4x increase from the prior two-year period.
- Radiology AI tools have the highest adoption rate at 34% of Canadian tertiary care centres, led by Aidoc’s critical finding detection platform.
- Canadian companies Trillium Health AI and PathogenomX are competing in the pathology AI segment against US-based Paige and PathAI.
- Health Canada has issued 27 AI diagnostic device clearances since January 2025, establishing a growing precedent base under its SaMD framework.
Canadian hospitals are in the middle of a procurement transformation that is happening faster than most industry observers predicted two years ago. Driven by a combination of radiologist shortages, pathology capacity constraints, diagnostic error reduction mandates, and federal digital health investment, hospital procurement budgets are being redirected toward AI-augmented diagnostic tools at a pace that is creating a material commercial opportunity. Total committed Canadian hospital spending on AI diagnostic tools reached an estimated $340 million in the 2025-2026 fiscal period a 240% increase from the $100 million committed in the prior two years.
The Radiology AI Adoption Wave
Radiology AI has the longest commercial history in Canadian hospitals, with the first Health Canada-cleared AI radiology tools arriving in 2021. The most widely deployed platform is Aidoc’s critical finding detection system, which continuously monitors CT scan queues and flags time-sensitive findings pulmonary embolism, intracranial haemorrhage, aortic dissection, large vessel occlusion for prioritized radiologist review. Aidoc is now deployed in 28 Canadian hospital networks across seven provinces, making it the single most widely adopted AI diagnostic platform in the country.
The radiology AI market has also attracted US-based Viz.ai (stroke and cardiovascular AI), Subtle Medical (image enhancement and dose reduction), and Enlitic (worklist prioritization and prior study comparison). Canadian-specific companies have found it more difficult to compete in radiology AI given the capital requirements for large-scale clinical validation and the network effects enjoyed by US-based platforms that validated in large US health systems first.
| Company | Platform | Application | Canadian Hospitals | HC Clearance |
|---|---|---|---|---|
| Aidoc (US) | aiOS platform | Critical finding detection (CT) | 28 networks | Yes (Class II) |
| Viz.ai (US) | Viz LVO, Viz PE | Stroke, pulmonary embolism | 14 networks | Yes (Class II) |
| Trillium Health AI (CA) | TriScan | Chest X-ray triage | 9 networks | Yes (Class II) |
| Paige (US) | Paige Prostate | Pathology AI (prostate) | 6 centres | Yes (Class III) |
| PathogenomX (CA) | PX-Path | Pathology AI (multi-cancer) | 4 centres (pilot) | Under review |
| Subtle Medical (US) | SubtlePET, SubtleMR | Image enhancement, dose reduction | 11 centres | Yes (Class II) |
Pathology AI: The Next Frontier
Radiology AI addresses images generated by machines. Pathology AI applying deep learning to digitized histology slides addresses images generated by human pathologists examining tissue samples under microscopes. The digitization of pathology workflows (a process called whole slide imaging) is a prerequisite for pathology AI deployment, and that infrastructure build is underway across Canadian centres, albeit at varying pace.
The Canadian pathology AI market is earlier-stage than radiology AI but moving quickly. PathogenomX, a Vancouver-based company founded by pathologists from the BC Cancer Agency, has developed a multi-cancer pathology AI platform that performs simultaneous tumour grading, biomarker scoring, and molecular subtype classification from H&E-stained slides. The company is running clinical pilots at four Canadian cancer centres and has submitted its Health Canada SaMD application for Class III device clearance a more stringent regulatory standard appropriate for diagnostic tools that directly influence treatment decisions.
Provincial Variation and Procurement Decision-Making
Hospital AI procurement in Canada is highly decentralized. Provincial health ministries set capital budget frameworks, but individual hospital networks make procurement decisions through their own technology assessment processes. This creates significant provincial variation in adoption rates. British Columbia has the most mature hospital AI procurement framework, supported by Health Data BC’s digital health infrastructure. Ontario’s hospital-based AI adoption has been accelerating since the provincial government’s 2024 Digital Health Action Plan committed $180 million to health system technology modernization.
The Bottom Line
The $340 million AI diagnostic procurement wave in Canadian hospitals is not a one-cycle phenomenon it is the beginning of a sustained capital deployment as the clinical evidence base matures, Health Canada’s SaMD clearance precedents accumulate, and hospital leadership increasingly views AI diagnostic tools as a necessary response to staffing shortages rather than an optional technology upgrade. For investors, the opportunity lies in identifying which Canadian companies can establish defensible positions in specific diagnostic categories before the market consolidates around a handful of dominant platforms, as has happened in the US radiology AI space.